StreetInsider.com News Articles

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the disease for a short time. For patients with aggressive tumors such as glioblastoma, treatment options remain limited, especially when cancer returns or stops responding to existing drugs. That is why drug developers are exploring new approaches, including targeted therapies, immunotherapy and advanced drug-delivery systems designed

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Wed, 21 Oct 2026 10:40:00 -0400

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

Aevex stock drops 5% as US Navy halts $130M drone boat program

Wed, 21 Oct 2026 07:13:36 -0400

Investing.com -- Shares of Aevex (NASDAQ: AVXL) fell 5% on Wednesday following reports that the U.S. Navy has suspended new orders for the company’s autonomous drone speedboats over ongoing performance issues.

According to a report from Bloomberg citing sources familiar with the matter, the Navy halted procurement of the Global Autonomous Reconnaissance Crafts (GARCs), manufactured by Aevex’s BlackSea Technologies unit. The decision comes after the Navy spent more than $130 million on the platform and commissioned an independent assessment of the program earlier this fall.

Aevex acquired BlackSea in September in a deal valued at

Aevex stock drops 5% as US Navy halts $130M drone boat program

Wed, 21 Oct 2026 07:13:36 -0400

Aevex acquired BlackSea in September in a deal valued at

Aevex stock drops 5% as US Navy halts $130M drone boat program

Wed, 21 Oct 2026 07:13:36 -0400

Aevex acquired BlackSea in September in a deal valued at

Aevex stock drops 5% as US Navy halts $130M drone boat program

Wed, 21 Oct 2026 07:13:36 -0400

Aevex acquired BlackSea in September in a deal valued at

Form 8-K ANAVEX LIFE SCIENCES For: Oct 20

Tue, 20 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261020/27210660.html

Anavex completes DDI and ADME studies for blarcamesine

Tue, 20 Oct 2026 16:00:55 -0400

Anavex Life Sciences Corp. (NASDAQ: AVXL) announced the completion of clinical conduct of two pharmacology studies of its drug candidate blarcamesine, according to a company press release dated Oct. 20, 2026.

The Drug-drug Interaction (DDI) study enrolled 65 healthy volunteers, all of whom received 30 mg of blarcamesine, with the last participant completing the study at the end of September. The Absorption, Distribution, Metabolism and Excretion (ADME) study enrolled 8 healthy volunteers, also receiving 30 mg of blarcamesine, with the last participant completing in mid-October. Based on preliminary observations, no serious adverse events were reported in either study. Full safety and

Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies

Tue, 20 Oct 2026 16:00:00 -0400

Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology characterization across pipeline programs

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical needs, today provided a corporate update highlighting progress across its three core indications for blarcamesine (ANAVEX 2-73): early Alzheimer’s disease, Rett syndrome and Fragile X syndrome. Recent Company highlights include the completion of clinical conduct of the Drug-drug Interaction (DDI) and Absorption, Distribution,

Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies

Tue, 20 Oct 2026 16:00:00 -0400

Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology characterization across pipeline programs

Form 8-K ANAVEX LIFE SCIENCES For: Oct 15

Thu, 15 Oct 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20261015/27193632.html

FDA clears Anavex IND for blarcamesine in Fragile X syndrome

Thu, 15 Oct 2026 16:00:39 -0400

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced it has received FDA clearance of its Investigational New Drug (IND) application for blarcamesine (ANAVEX®2-73) in Fragile X syndrome (FXS), allowing the company to proceed with clinical trials in the United States.

The clearance gives Anavex open INDs across three indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Blarcamesine has previously received Orphan Drug Designation from the FDA for the treatment of FXS.

According to the company's statement, Anavex plans to conduct a Phase 2a randomized, double-blind, placebo-controlled, dose-ranging study designated ANAVEX2-73-FXS-001. The trial will evaluate the safety, tolerability, and pharmacokinetics of blarcamesine oral

FDA clears Anavex IND for blarcamesine in Fragile X syndrome

Thu, 15 Oct 2026 16:00:39 -0400

Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome

Thu, 15 Oct 2026 16:00:00 -0400

Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome

Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral solution in adult males with Fragile X syndrome

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the Company may proceed

Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome

Thu, 15 Oct 2026 16:00:00 -0400

Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome

Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral solution in adult males with Fragile X syndrome

Form 3 ANAVEX LIFE SCIENCES For: Sep 24 Filed by: Senderowicz Adrian

Mon, 05 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261005/27149692.html

Form 3 ANAVEX LIFE SCIENCES For: Sep 24 Filed by: Patel Gautam

Mon, 05 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261005/27148733.html